The Interesting Company That Produces An Anti-Aging Pill

Summary

ChromaDex has a product that can has multiple health benefits, including resistance to weight gain, improved control of blood sugar and cholesterol, reduced nerve damage, and longer lifespan.

If trials show positive results in humans, the company can go from a micro-cap stock to an industry leader.

A hearty amount of billionaires are betting on ChromaDex to win.

ChromaDex (NASDAQ:CDXC) is working on some truly "sci-fi" technology, and investors love it. CDXC is a low-volume, micro-cap stock that focuses on health products. I usually advise investors to stay away from these "day trader putty" stocks, as they usually move when big traders want them to, and the underlying companies are worthless. However, ChromaDex is not worthless. In fact, this company could be worth quite a lot in the future, if it plays its cards right.

ChromaDex is a biotech company focusing on proprietary ingredient technologies and intellectual property that address the dietary supplement, skin care and pharmaceutical markets. It has relationships with leading universities and research institutions (such as UIHC and UC Boulder) and is able to discover and acquire early-stage ingredient technologies that are protected by intellectual property. The company owns ingredient technologies such as NIAGEN nicotinamide riboside; pTeroPure pterostilbene and; PURENERGY, a caffeine-pTeroPure co-crystal. Five of its products are for sale to the public.

The Company’s Most Interesting Product - NIAGEN

While ChromaDex does have some interesting products, NIAGEN is what will make it go from a micro-cap unknown company to an industry leader.

NIAGEN, also known as nicotinamide riboside (NR), is a newly discovered form of Vitamin B3. The body converts NR into Nicotinamide Adenine Dinucleotide (NAD+), which is an essential molecule found in every living cell. The human body has the highest NAD+ levels at birth; as the body ages, these levels significantly decrease.

According to a University Of Iowa clinical trial, researchers have shown that NR is safe for humans and increases levels of the cell metabolite, NAD+, that is critical for cellular energy production and protection against stress and DNA damage. There was never a trial on humans done before this research which was done in collaboration between ChromaDex, Queens College and the University of Iowa. Previously, “studies in mice have shown that boosting the levels of this cell metabolite - known as NAD+ - can produce multiple health benefits, including resistance to weight gain, improved control of blood sugar and cholesterol, reduced nerve damage, and longer lifespan. Levels of NAD+ diminish with age, and it has been suggested that loss of this metabolite may play a role in age-related health decline,” started a research report published in the ScienceDaily research news publication.

"Now that we have demonstrated safety in this small clinical trial, we are in a position to find out if the health benefits that we have seen in animals can be reproduced in people," said Dr. Brenner, the lead researcher and a consultant to ChromaDex.

Multiple long-term clinical trials are in progress to see what effects increased NAD+ levels have on humans. If they replicate what has already been proven true with mice, NIAGEN may very well be an anti-aging pill. It could also be used to treat Alzheimer's, high cholesterol and other various ailments. This could be a major turning point in ChromaDex's history, as the company would see a much higher demand for its product, and because it controls the intellectual property relating to NR technologies, CDXC could move from a micro-cap to a small/mid-cap stock in a matter of months.

This potential from an investor's point of view can be seen by looking at CDXC on a graph. Each time there is a pivotal event, investors take note and buy in. On September 7th, ChromaDex partnered with Watsons for the TRU NIAGEN retail launch in Asia - and shares jumped almost 50%.

Each One Of These Could Be A Catalyst

(Source)

Q3 Earnings Report

The Q3 earnings call gave the company a lot more clarity. Financially it was very strong, reporting net sales of $6.1 million, which are up by 55% as compared to net sales of $3.9 million for the third quarter of 2016. Revenues related to NIAGEN were $4.5 million, which represented 73% of third-quarter net sales. Gross profit improved for the third quarter of 2017 at 47.9%, as compared to the third quarter of 2016 at 47.3%.

Operating expenses for the quarter were up by $3.3 million to $6.1 million, as compared to the third quarter of 2016 of $2.8 million, mainly due to the fact that CDXC is investing more in marketing, research & development. “As revenue and available financial resources continue to grow, the company plans to continued increase research and developmental efforts,” stated Kevin Farr, CFO, in the earnings call. This is great, as companies need to spend money to make money, and their spending remains proportional to their revenue.

The earnings call also reveals that the company is looking to file an IND relating to a Cockayne Syndrome cure/treatment using NIAGNEN’s technology. Cockayne Syndrome is a fatal neuro-degenerative disease which impairs the development of the nervous system. It also results in premature ageing, and most affected people usually do not survive past childhood. “We're pretty heavily focused on finalizing what we need to go for the IND. And now that we have finalized the last IND-enabling study, the IND-enabling study was designed around what we expect at least from a study-design standpoint,” stated Rob Fried, president and CSO. The company is on track to file by the end of 2017, and though it is a rare disease, if the drug is effective, it could be a very lucrative business opportunity.

ChromaDex is also focusing on building an international brand to sell NAIGEN directly to the consumer, called TRU NIAGEN. “Our main focus in 2018 is to grow TRU NIAGEN around the world,” stated Mr. Fried. To ensure the success of the brand, the company is reducing the number of NIAGEN brands in the marketplace. In March, it had more than 20 resellers of NIAGEN, which sold the products under their own brand name. “We have terminated the supply agreements to all but seven, and expect it to be less than five by year's end,” stated Mr. Fried in the earnings call.

Billionaire Investors and Influential Management

To further add to the "interestingness" of this company, we can take a look at its investors. Phillip Frost holds a total of 7.04% interest in the company and is the CEO and chairman of Opko Health, Inc., a biotech company with a market cap of $3.07 billion. Michael H. Brauser, a chairman in Cogint, has a 6.1% stake.

Now if we head over to ventures and funds that have invested in CDXC, it becomes even more interesting. Champion River Ventures, Ltd. is the largest investor in the company, controlling 12.0% interest as of November 3rd. CRV is directly controlled by Li Ka-shing, who is its sole shareholder and Hong Kong's richest person. A recent purchase agreement also shows that ICONIQ Capital (along with others) want in as well. ICONIQ Capital is Silicon Valley’s billionaire investors club. “Notable clients include Facebook CEO Mark Zuckerberg, Facebook COO Sheryl Sandberg, Napster founder Sean Parker, and Twitter/ Square CEO Jack Dorsey, among other high net-worth individuals,” states this research article.

For more information on the billionaires betting on ChromaDex, read thisarticle by a fellow Seeking Alpha contributor.

If we look at recent management changes, Kevin Farr was welcomed to the company as the chief financial officer. Mr. Farr joined the company from Mattel, where he spent the last 17 years as executive vice president and CFO. When asked why he moved from the seven billion dollar company to ChromaDex, he responded that:

“I'm a believer in NR and TRU NIAGEN, and I think there's a huge global opportunity. And look, I've been in the business for quite a while, and [I’m] done big large-cap companies. So I was quite excited to join the team with Frank and Rob. And I think the team is more entrepreneurial, and I think it's a great opportunity for us to grow a global brand and create a large company and be very successful.”

Mr. Fried told investors to “expect more management additions to come.”

Risks

Something that worried me occurred in the Q&A section of the Q3 earnings report, where a representative from Ladenburg Thalmann asked the following questions:

“How much more inventory, residual inventory do they have? Approximately how many quarters?... For the Watsons deal, you said they have approximately 6,000 stores. Is your product in all 6,000 of those? Or have you picked specific areas or specific stores for strategic purposes?”

In response to the inventory question, Mr. Fried answered:

“We don't know exactly how much inventory they have. We don't know their exact consumer sales.”

For the question regarding the Watsons stores, he replied:

“They have approximately 100 stores in Hong Kong and we believe it's in all of those 100 stores in Hong Kong... We expect that they will be because they are investing fairly effectively and aggressively in marketing. But we don't know the answer to that.”

This lack of knowledge reminded me that this is not a giant Wall St. powerhouse or an international biotech company. It is a thinly traded micro-cap stock which has the potential to maybe do something big. This is a risky investment. Investors buying in now need to remember this fact, and the fact that while it is a real company that can see some real growth, currently the stock is still in the realm of "day trader putty." It will go up and down, sometimes drastically.

(However, I would like to mention that this earnings call was very professional for a micro-cap company, and CDXC has great shareholder communications.)

Conclusion

Despite the risks, I do own a small position in the company. I will advise, however, to only invest money that you are OK with losing in the short term. It is a risky bet, but I feel it is worth this risk. If NAD+ is proven to have long-term anti-ageing benefits, ChromaDex will go from a micro-cap to an industry leader (and a tasty acquisition target).

Also, you can invest with the peace of mind that some really wealthy investors want this company to succeed.

Disclosure: I am/we are long CDXC.

By Wappinger Capital Research

Source: https://goo.gl/cLYstC

How Did Cryptocurrencies Perform Compared to Stocks in 2017?

Cryptocurrency enthusiasts are quick to point out the massive gains in the space, particularly over the last year. Major digital currencies like bitcoin climbed by orders of magnitude of value in the span of months. Traditional investors, though, are perhaps more likely to exercise caution when it comes to digital currency investments. Some of the biggest names in investing have warned that digital currencies are nothing more than the latest bubble. (See more: Is Bitcoin In Bubble Territory?)

With 2017 behind us, we can now explore just how well stocks and cryptocurrencies performed relative to one another during that time.

Compare: 117.7% vs 28,963%

According to a report by Coin Telegraph, the cryptocurrency world left the stock world in the dust when it came to overall performance in 2017. For an example, compare the top-performing stock market for the year with the top-performing virtual currency at the same period.

In the case of stocks, this would be the Zimbabwe market, which advanced by 117.7% (this is not including the Venezuela market due to inflation). By comparison, the top-performing cryptocurrency, Ripple, managed to win 28,963% returns for the same period. Ripple began 2017 at $0.0065 per token and ended the year at roughly $2.25. In the process, Ripple, passed by ether to become the second-largest digital currency by market cap, following only bitcoin.

Ripple was not the only digital currency to experience outlandish gains, although it did have the largest percentage increase for the year. Ethereum's ether token rose by about 1,300%, while bitcoin climbed by just under 500% from the beginning of 2017 to the start of 2018. Many digital currencies saw major spikes in value toward the end of the year.

Among Stocks, Emerging Markets Soared

In the world of stocks, less developed and emerging markets were the ones that posted the largest gains in 2017. Argentina saw a 77.7% return, while Mongolia gained 68.9% and Kazakhstan rose by 59.3%. This may be trivial for some investors, as there are barriers to investments in many of these markets. Still, in spite of these generally impressive results, the returns were meager compared with those in the digital currency space.

The fact that there are international barriers to stock market investments may also play into the rise in popularity of digital currencies, too. Because virtual currencies are largely unregulated and decentralized, investors can participate in markets all over the world with ease. They can access their investments and transact at any time of day.

Investing in cryptocurrencies and other Initial Coin Offerings (“ICOs”) is highly risky and speculative, and this article is not a recommendation by Investopedia or the writer to invest in cryptocurrencies or other ICOs. Since each individual's situation is unique, a qualified professional should always be consulted before making any financial decisions. Investopedia makes no representations or warranties as to the accuracy or timeliness of the information contained herein. As of the date this article was written, the author owns cryptocurrency.

Source: https://goo.gl/Bd716E

Top 4 Technology Penny Stocks to Watch

Technology remains fertile ground for young companies to try their hand at putting new tech solutions on the market. That means investors will find plenty of penny stocks to choose from. If you want to learn more about the process of trading penny stocks, Investopedia has a day trading course.

We have selected four penny tech stocks for you to consider. These stocks were chosen based on their positions in their industries. In other words, we looked for stocks that have the potential to capture market share. All figures are current as of Jan. 4, 2018. (See also: How to Pick Winning Penny Stocks.)

Zix Corporation (ZIXI)

Zix is an email provider. It focuses on secure messaging, marketing itself to corporate and government entities. The unique approach of encryption, coupled with avoiding downloading, makes this an attractive service.

With sales rising 65% in five years, Zix is making headway. It tends to range in and out of the penny stock category, as it rises over $5 per share on occasion. As you might expect, the company is very small, with a market cap of just over $247 million. Revenues have been increasing steadily over the past four years. With earnings per share (EPS) in the positive column, this stock shows promise for investors who are willing to take on the risk of a penny stock. (For more, see: How to Invest in Penny Stocks.)

• Average Volume: 237,485
• Market Cap: $247.122 million
• P/E Ratio (TTM): 35.35
• EPS (TTM): $0.13

Glu Mobile Inc. (GLUU

GLUU

Glu Mobile Inc

3.63

-0.41%

 

) 

Glu Mobile makes games for smartphones. It has multiple titles that are gaining popularity for players who use phones or tablets. Many of the titles are based on action movies, while others are based on existing console games. Interestingly, its biggest selling title is a casual role-playing game based on the life of reality TV star Kim Kardashian.

The company has worked its way out of debt and has strong cash reserves. Revenues have been rising over the past four quarters, but operating income is negative. Glu Mobile is spending on research and development to find its next hit. The potential for this stock is based on its industry, as games continue to grow in popularity and gamers are willing to try new games even if they are not from large companies. If Glu Mobile comes up with a hit game, it will likely send the stock soaring. (See also: Glu Mobile Buys Game Company Plain Vanilla.)

• Average Volume: 4,357,130
• Market Cap: $501.544 million
• P/E Ratio (TTM): -6.54
• EPS (TTM): -$0.56

Arotech Corporation (ARTX

ARTX

Arotech Corp

3.48

-0.71%

 

)

This company has combined two of the hottest trends around today: drones and virtual reality. It creates technology for the military and law enforcement, offering simulations for use-of-force training. It also sells to the security and emergency services sectors. The company provides weapons simulations for aircraft and missile systems.

Arotech has positioned itself as a significant provider of surveillance and attack technologies at a time when drones are gaining increased attention and artificial intelligence is being deployed. After several quarters of flat performance, revenue ticked up in the quarter that ended Sept. 30, 2017, and the company's operating income turned positive during that period. These are positive signals for Arotech, and the stock could offer room for additional growth based on the potential for the company and the sector. (For more, see: Top 6 Drone Stocks.)

• Average Volume: 177,241
• Market Cap: $91.647 million
• P/E Ratio (TTM): -35.3
• EPS (TTM): -$0.10

Plug Power Inc. (PLUG

PLUG

Plug Power Inc

2.38

-1.86%

 

)

Plug Power is a player in the burgeoning alternative energy industry, focusing on the field of hydrogen fuel cell technology. The company provides fuel cell solutions to the material handling and stationary power sectors. Based in Latham, New York, Plug Power has been in existence since 1997, indicating that there is some longevity to the story despite its current status as a penny stock.

Operating income has been consistently negative for the past few years, and that trend continued in 2017. However, the stock price appears to have reached a bottom in the first few months of 2017, and it broke out in March and April on strong trading volume, with the shares doubling in value over that time frame. Although Plug Power saw its share price slide downward in November, the stock could offer investors solid gains as the alternative energy industry gathers strength. (See also: Penny Stocks to Watch.)

• Average Volume: 4,744,582
• Market Cap: $549.47 million
• P/E Ratio (TTM): -3.79
• EPS (TTM): -$0.64

The Bottom Line

The trouble with penny stocks is that investors have to make some guesses about the future. Very few penny stocks have a strong enough track record to indicate that they will survive and prosper. That said, the penny stocks on our list operate in significant industries and have the potential to be vital players in those industries.

Source: https://goo.gl/LHYywe

New Strong Buy Stocks for December 12th

MGLN CZZ CONN BV AVGO

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:

Conn's, Inc. (CONN - Free Report) : This specialty retailer of durable consumer goods and related services has seen the Zacks Consensus Estimate for its current year earnings increasing 7.6% over the last 60 days.

Conn's, Inc. Price and Consensus

Conn's, Inc. price-consensus-chart | Conn's, Inc. Quote

Cosan Limited (CZZ - Free Report) : This company that engages in the fuel and natural gas distribution, logistics, lubricant, sugar and ethanol, and fuel businesses has seen the Zacks Consensus Estimate for its current year earnings increasing more than 100% over the last 60 days.



Magellan Health, Inc. (MGLN - Free Report) : This company that engages in the healthcare management business has seen the Zacks Consensus Estimate for its current year earnings increasing 9.6% over the last 60 days.

Magellan Health, Inc. Price and Consensus

Magellan Health, Inc. price-consensus-chart | Magellan Health, Inc. Quote

Bazaarvoice, Inc. (BV - Free Report) : This provider of marketing tools to retailer and brand clients has seen the Zacks Consensus Estimate for its current year earnings increasing 37.5% over the last 60 days.

Bazaarvoice, Inc. Price and Consensus

Bazaarvoice, Inc. price-consensus-chart | Bazaarvoice, Inc. Quote

Broadcom Limited (AVGO - Free Report) : This developer of a range of semiconductor devices clients has seen the Zacks Consensus Estimate for its current year earnings increasing 4.8% over the last 60 days.

Broadcom Limited Price and Consensus

Broadcom Limited price-consensus-chart | Broadcom Limited Quote

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here

More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.

Click here for the 6 trades >>

Source: https://goo.gl/qpVuMS

Today's Stock Upgrades And Downgrades

Upgrades

• Rosneft (OJSCY) upgraded by Goldman Sachs from Neutral to Buy
• Verizon (VZ) upgraded by Nomura Instinet from Neutral to Buy
• Teradyne (TER) upgraded by Goldman Sachs from Neutral to Buy
• Entergy (ETR) upgraded by BofA/Merrill from Neutral to Buy
• M&T Bank (MTB) upgraded by UBS from Sell to Neutral
• Coty (COTY) upgraded by Citi from Neutral to Buy
• Tenet (THC) upgraded by Citi from Neutral to Buy
• Universal Health (UHS) upgraded by Citi from Neutral to Buy
• Activision Blizzard (ATVI) upgraded by Goldman Sachs from Neutral to Buy

Downgrades

• Spark Therapeutics (ONCE) downgraded by UBS from Buy to Neutral
• Bluerock Residential (BRG) downgraded by Janney Capital from Buy to Neutral
• U.S. Bancorp (USB) downgraded by UBS from Buy to Neutral
• Michaels (MIK) downgraded by Deutsche Bank from Buy to Hold
• Columbia Sportswear (COLM) downgraded by Goldman Sachs from Buy to Neutral
• Electronic Arts (EA) downgraded by Goldman Sachs from Conviction Buy to Buy
• Oasis Petroleum (OAS) downgraded by SunTrust from Buy to Hold
• MoneyGram (MGI) downgraded by JPMorgan from Neutral to Underweight
• Web.com (WEB) downgraded by JPMorgan from Overweight to Neutral
• ServiceNow (NOW) downgraded by JPMorgan from Overweight to Neutral
• GoDaddy (GDDY) downgraded by JPMorgan from Overweight to Neutral
• Adobe (ADBE) downgraded by JPMorgan from Overweight to Neutral
• Barracuda (CUDA) downgraded by JPMorgan from Overweight to Neutral

Source: https://goo.gl/FjiFzm

IPO News This Week: Another Week with 10 More Firms Seeking Entry into the Capital Markets

There were 10 initial public offerings (IPOs) on the calendar last week and 10 firms succeeded in gaining access to the public markets although a couple of those scheduled were delayed and a couple of others stepped up. The total amount raised reached a combined $1.6 billion and the average first-day pop was around 10%, a bit below the 13% average, but none of last week's IPOs broke issue and closed lower than the offering price.

There are 10 more IPO's on the coming week's calendar and they are looking to raise a combined total of about $1.9 billion. This is the last big week for IPOs before Thanksgiving and probably the last for the year.

Here's a recap of last week's IPOs:

CBTX Inc. (CBTX) raised $62 million on the sale of 2.4 million shares at $26, the high end of the expected range. Shares popped 10% on the IPO and closed the week up 12%.

Meridian Bank (NASDAQ:MRBK) raised $40 million on the sale of 2.4 million shares at $17, the low end of the expected range. Shares popped 7% on the Friday IPO.

Sogou Inc. (SOGO) sold 45 million shares at $13, the high end of the expected range, raising $585 million. Shares popped 4% on the IPO and closed the week up 7%.

Erytech Pharmaceuticals (ERYP) raised $109 million on the sale of 4.7 million shares priced at $23.26. Shares popped 6.4% on the Friday IPO.

Bandwidth Inc. (BAND) ) raised $80 million on the sale of 4 million shares at $20 a share, the low end of the range. Shares popped 6% on the Friday IPO.

Metropolitan Bank Holding (MCB) raised $109 million on the sale of 3.1 million shares at $ 35, above the expected range. Shares added 6% on the Friday IPO.

PPDAI Group Inc. (PPDF) raised $221 million on an offering of 17 million shares at $13, below the expected range. Shares added 1% on the IPO on the Friday IPO.

Apellis Pharmaceuticals Inc. (APLS) raised $150 million on the sale of 10.7 million shares at $14, the mid-point of the expected range. Shares closed flat on the Thursday IPO and flat for the week.

Four Seasons Education (Cayman) Inc. (FEDU) raised $101 million on its offering of 10.1 million shares prices at $10, the mid-point of the expected range. Shares dropped 5% on the IPO and closed the week flat.

InflaRX (IFRX) raised $100 million on the sale of 6.7 million shares at $15, the mid-point of the expected range. Shares closed the week unchanged.

Through the week ending November 10, IPO ETF manager Renaissance Capital reported that 141 IPOs have priced in the U.S. so far this year, up nearly 47% year over year. Total proceeds raised through last week equaled $33.2 billion, up nearly 98% year over year.

For 2016, Renaissance Capital reported a total of 105 IPOs, down 38% year over year from 170 in 2015. Total 2016 proceeds amounted to $18.8 billion compared with a 2015 total of $30 billion. Renaissance Capital does not include “best efforts” or blank-check companies in its totals, nor does it include IPOs that raise less than $10 million.

Here are the 10 companies seeking a place in the public markets next week.

SendGrid Inc. is a cloud-based digital communications platform for businesses. The company plans to offer 7.7 million shares in an expected price range of $13.50 to $14.50 to raise $112 million at a market cap of $584 million. Underwriters are Morgan Stanley, J.P. Morgan, William Blair, KeyBanc Capital Markets, Piper Jaffray, and Stifel. Shares are set to price Tuesday and begin trading Wednesday on the New York Stock Exchange under the ticker symbol SEND.

ALSO READ: America's Best States to Live In

Arsanis Inc. is a clinical-stage biopharmaceutical company developing monoclonal antibody immunotherapies for serious infectious diseases. The company plans to offer 3.1 million shares in an expected price range of $15 to $17 to raise $15 million. Underwriters are Citi, Cowen & Co., and Piper Jaffray. Shares are expected to price Wednesday and begin trading Thursday on the Nasdaq under the ticker symbol ASNS.

Jianpu Technology Inc. is an online consumer loan and credit platform based in Beijing. The company plans to offer 22.5 million shares in an expected price range of $8.50 to $10.50 to raise $214 million at a market cap of $1.6 billion. Underwriters are Goldman Sachs (Asia), Morgan Stanley, J.P. Morgan, and China Renaissance. Shares are expected to price Wednesday and begin trading Thursday on the New York Stock Exchange under the ticker symbol JT.

MPM Holdings Inc. is a producer of specialty silicones and other chemical additives. The company plans to sell 14.6 million shares in an expected price range of $23 to $25 to raise $350 million at a market cap of $1.4 billion. Shares already trade on the OTCQX market place under the ticker symbol MPMQ. Underwriters include J.P. Morgan, Goldman Sachs, Credit Suisse, Deutsche Bank, UBS Investment Bank, Wells Fargo Securities, and BMO Capital Markets. Shares are expected to price Wednesday and begin trading Thursday on the New York Stock Exchange under the ticker symbol MPMH.

Bluegreen Vacations Corp. sells timeshares and manages resorts in the United States. The company plans to offer 6.5 million shares in an expected price range of $16 to $18 to raise $111 million at a market cap of $1.3 billion. Underwriters are Stifel, Credit Suisse, BofA/Merrill Lynch, and SunTrust Robinson Humphrey. Shares are set to price Thursday and begin trading Friday on the New York Stock Exchange under the ticker symbol BXG.

Legacy Acquisition Corp. is a blank-check company seeking to make its first acquisition. The company plans to offer 30 million units at $10 per unit to raise $300 million at a market cap of $375 million. Each unit consists of one share of common stock and one warrant to purchase one-half of one share exercisable at $11.50. Underwriters are Wells Fargo Securities, Cantor Fitzgerald, Stifel, and Loop Capital Markets. Units are set to price Thursday and begin trading Friday on the New York Stock Exchange under the ticker symbol LGCU.

Molino Cañuelas SACIFIA is a leading Argentina-based food producer. The company plans to offer 19.5 million shares in an expected range of $14 to $16 to raise $293 million at a market cap of $940 million. Underwriters are J.P. Morgan, UBS Investment Bank, HSBC Corp., and ITAU BBA. Shares are expected to price Thursday and begin trading Friday on the New York Stock Exchange under the ticker symbol MOLC.

Sailpoint Technologies Holdings Inc. is a provider of identity governance software for enterprise clients. The company plans to offer 20 million shares in an expected price range of $9 to $11 to raise $200 at a market cap of $896 million. Underwriters are Morgan Stanley, Citi, Jefferies, RBC Capital Markets, KeyBanc Capital Markets, Canaccord Genuity, and Oppenheimer & Co. Shares are set to price Thursday and begin trading Friday on the New York Stock Exchange under the ticker symbol SAIL.

scPharmaceuticals Inc. is developing and commercializing an injectable version of an intravenous drug for heart failure. The company plans to offer 6.4 million shares in an expected price range of $14 to $16 to raise $96 million at a market cap of $264 million. Underwriters are Jefferies, Leerink Partners, and BMO Capital Markets. Shares are set to price Thursday and begin trading Friday on the Nasdaq under the ticker symbol SCPH.

Stitch Fix Inc. is an online personal style and clothing retailer. The company plans to offer 10 million shares in an expected price range of $18 to $20 to raise $190 million at a market cap of $1.8 billion. Underwriters are Goldman Sachs, J.P. Morgan, Barclays, RBC Capital Markets, Piper Jaffray, Stifel, and William Blair. Shares are set to price Thursday and begin trading Friday on the Nasdaq under the ticker symbol SFIX.

Source: https://goo.gl/g59Ley